Biogen Inc. and closely held Banner Life Sciences LLC agreed to drop a lawsuit in which Biogen had said Banner’s proposed Bafiertam capsules would infringe patents related to the blockbuster multiple sclerosis drug Tecfidera.
The stipulation of voluntary dismissal, ordered Sept. 20 in federal court in Wilmington, Del., included no mention of a settlement.
Tecfidera had U.S. sales of $1.55 billion in the first six months of 2018, down from $1.63 billion during the same period in 2017, Biogen said July 24 in its quarterly earnings report.
Tecfidera’s $3.3 billion of U.S. sales in 2017 accounted for 26.8 percent of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.